New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
12:11 EDTAMGNAmgen sees FY12 EPS $6.40-$6.50, consensus $6.59
Says R&D Tax Credit will be reflected in 2013 results.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
18:35 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTAMGNAmgen says total product sales increased 8% in Q2
Total product sales increased 8% for the second quarter of 2014 versus the second quarter of 2013. The increase was mainly driven by ENBREL, Kyprolis, Prolia and XGEVA. Product sales in the second quarter of 2013 included a positive adjustment of $185M to previous estimates for managed Medicaid rebates based on claims experience.
16:21 EDTAMGNAmgen to reduce global workforce by 12%-15%
The company announced a restructuring plan today to invest in continuing innovation and the launch of its new pipeline molecules, while improving its cost structure. Initial efforts include streamlining the organization, reducing layers of management, increasing managerial spans of responsibility and beginning implementation of a revised geographic site plan. As a first step, the company will reduce staff by 2,400-2,900, beginning later this year and continuing through 2015, predominantly in the U.S. This represents approximately 12% to 15% of Amgen’s global workforce. The company will also close its facilities in the states of Washington and Colorado
16:19 EDTAMGNAmgen raises FY14 EPS view to $8.20-$8.40 from $7.90-$8.20, consensus $8.09
Subscribe for More Information
16:16 EDTAMGNAmgen reports Q2 EPS $2.37, consensus $2.07
Reports Q2 revenue $5.18B, consensus $4.9B.
15:53 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:49 EDTAMGNEarnings Preview: Amgen counting on newer drugs to boost sales
Subscribe for More Information
11:11 EDTAMGNAmgen technical comments before results
Subscribe for More Information
July 25, 2014
09:19 EDTAMGNAmgen weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:36 EDTAMGNEMA adopts positive opinion on new indication for Xgeva
Subscribe for More Information
05:35 EDTAMGNBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information
July 17, 2014
16:10 EDTAMGNAmgen announces positive Phase 3 results for AMG 416
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use